Presentation is loading. Please wait.

Presentation is loading. Please wait.

Mechanism-Based Precision Therapy for the Treatment of Primary Immunodeficiency and Primary Immunodysregulatory Diseases  Jennifer W. Leiding, MD, Lisa.

Similar presentations


Presentation on theme: "Mechanism-Based Precision Therapy for the Treatment of Primary Immunodeficiency and Primary Immunodysregulatory Diseases  Jennifer W. Leiding, MD, Lisa."— Presentation transcript:

1 Mechanism-Based Precision Therapy for the Treatment of Primary Immunodeficiency and Primary Immunodysregulatory Diseases  Jennifer W. Leiding, MD, Lisa R. Forbes, MD  The Journal of Allergy and Clinical Immunology: In Practice  Volume 7, Issue 3, Pages (March 2019) DOI: /j.jaip Copyright © 2019 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Figure 1 Jakinib inhibition of JAK-STAT signaling: Cytokines bind their respective receptors and activate janus tyrosine kinase (JAK) proteins, which, in turn, phosphorylate STAT transcription factors to homodimerize or heterodimerize to the nucleus where they direct gene transcription.Shown in this figure are selected cytokines and the corresponding JAK-STAT signal activated. Further shown is where specific JAK inhibitors (Jakinibs) inhibit the activated JAK protein. *IL-2 and IL-15 receptor each have 3 chains. †IL-27 signals through the gp130 receptor chain and can activate STAT1, STAT3 and STAT5. EPO, erythropoietin; JAK, janus kinase. The Journal of Allergy and Clinical Immunology: In Practice 2019 7, DOI: ( /j.jaip ) Copyright © 2019 American Academy of Allergy, Asthma & Immunology Terms and Conditions


Download ppt "Mechanism-Based Precision Therapy for the Treatment of Primary Immunodeficiency and Primary Immunodysregulatory Diseases  Jennifer W. Leiding, MD, Lisa."

Similar presentations


Ads by Google